EGFR and cancer: Moreover, tumor-synthesized VEGF is an important immunosuppressive cytokine for eluding immunosurveillant cells (e.g., NK cells, T cells, and so on) (Dunn et al., 2006; Matsueda and Graham, 2014; Nam and Park, 2012), and MET and EGFR are also strong therapeutic target candidates in numerous cancers, including those of the lung and colorectum (Cataisson et al., 2016; Gou et al., 2016; Misale et al., 2014; Pietrantonio et al., 2016; Shida et al., 2004; Takahashi et al., 2016).